Scope
KDIGO’s 2025 update treats IgA nephropathy through simultaneous disease-directed therapy and protection of remaining kidney function. Proteinuria from 0.5 g/day marks meaningful progression risk, with lower proteinuria goals and dynamic reassessment. The guideline distinguishes IgAN variants, IgA vasculitis nephritis and paediatric disease rather than applying one immunosuppressive pathway to all.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm disease and assess progression risk
- IgA nephropathy requires kidney biopsy; there is no validated diagnostic blood or urine biomarker. Consider biopsy in adults with proteinuria at least 0.5 g/day when IgAN is possible and biopsy is not contraindicated, then assess secondary causes. [1]
- Use clinical data and Oxford MEST-C biopsy findings for risk assessment. The International IgAN Prediction Tools estimate progression risk up to 7 years from biopsy, but they must not be used to select a specific treatment regimen. [1]
- Consider treatment or additional treatment when proteinuria remains at least 0.5 g/day on or off therapy. Aim to maintain proteinuria below 0.5 g/day, ideally below 0.3 g/day, recognizing that extensive scarring may limit what is achievable. [1]
- Reassess risk dynamically. Do not choose immunosuppression solely from the presence or number of crescents; interpret pathology together with clinical findings, particularly the rate of eGFR change. [1]
Combine disease-directed treatment with kidney protection
- Advise dietary sodium below 2 g/day, smoking and vaping cessation, appropriate weight control and endurance exercise. Target blood pressure at or below 120/70 mmHg and assess cardiovascular risk. [1]
- Use an optimized maximally tolerated ACE inhibitor or ARB for IgAN unless contraindicated, including by low blood pressure, bilateral renal artery stenosis or hyperkalaemia. Kidney-protective treatment should not preclude appropriate disease-directed treatment. [1]
- KDIGO suggests sparsentan for IgAN at risk of progressive kidney-function loss. Do not combine it with an ACE inhibitor or ARB: its dual action already includes renin–angiotensin blockade. Approval and availability differ by country. [1]
- KDIGO suggests an SGLT2 inhibitor for IgAN at risk of progression. Explain that evidence is less certain in younger patients with relatively preserved kidney function, particularly eGFR above 60 mL/min/1.73 m². [1]
Discuss disease-specific treatment and toxicity
- KDIGO suggests a 9-month course of Nefecon targeted-release budesonide for patients at risk of progressive IgAN. A course may not produce sustained proteinuria or eGFR benefit, and safety and efficacy of repeated courses remain uncertain. [1]
- For IgAN at risk of progressive kidney-function loss where Nefecon is unavailable, KDIGO suggests a reduced-dose systemic glucocorticoid course with antimicrobial prophylaxis. The specified methylprednisolone regimen is 0.4 mg/kg/day, maximum 32 mg/day, for 2 months, then tapering by 4 mg/day each month over a total of 6–9 months. [1]
- Systemic glucocorticoids require Pneumocystis prophylaxis, antiviral prophylaxis for hepatitis B carriers, and gastric and bone protection according to national guidance. Review toxicity risks before choosing this strategy. [1]
- Glucocorticoid toxicity is more likely with eGFR below 30 mL/min/1.73 m², diabetes or prediabetes, obesity, latent hepatitis or tuberculosis, active peptic ulceration, uncontrolled psychiatric illness, osteoporosis or cataracts. [1]
- Do not generalize population-specific treatments: evidence for mycophenolate or hydroxychloroquine is insufficient in non-Chinese patients, and tonsillectomy should not be used to treat IgAN in non-Japanese patients. [1]
Recognize situations needing a different pathway
- If IgA deposits coexist with otherwise minimal-change-disease morphology and nephrotic syndrome, use the minimal-change-disease pathway. Nephrotic syndrome with mesangioproliferative findings instead follows the progressive-IgAN pathway. [1]
- Treat visible-haematuria-associated AKI supportively and consider repeat biopsy if kidney function has not improved within 2 weeks after haematuria stops. Suspected rapidly progressive disease needs urgent evaluation for alternative and reversible causes. [1]
- Rapidly progressive IgAN means at least a 50% eGFR decline within 3 months after exclusion of alternative and reversible causes. Biopsy is essential; offer cyclophosphamide with systemic glucocorticoids using the ANCA-vasculitis approach. Crescents without declining kidney function alone do not establish this diagnosis. [1]
- Offer preconception counselling and review cessation of RAS blockers, SGLT2 inhibitors, sparsentan, Nefecon and systemic glucocorticoids, with alternative blood-pressure control before conception. Do not use SGLT2 inhibitors or sparsentan while breastfeeding; enalapril can be used when a RAS blocker is indicated. [1]
Separate IgA vasculitis nephritis from IgAN
- In adults with suspected IgA vasculitis, biopsy for kidney impairment, rapidly progressive disease or proteinuria at least 0.5 g/day persisting more than 4 weeks. Assess secondary causes and use age- and sex-appropriate malignancy screening. [1]
- Do not use systemic glucocorticoids to prevent nephritis in isolated extrarenal IgA vasculitis. IgAV nephritis at risk of progression needs individualized benefit–harm discussion; if systemic glucocorticoids are chosen, use a reduced-dose regimen with antimicrobial prophylaxis. [1]
- Do not apply the International IgAN Prediction Tools to IgAV-nephritis prognosis. Rapidly progressive IgAV nephritis needs individualized immunosuppression assessment; associated pulmonary, gastrointestinal or skin disease may alter the treatment strategy. [1]
Use paediatric assessment and long-term surveillance
- Children with persistent or recurrent haematuria plus nephrotic-range proteinuria or reduced eGFR need prompt IgAN biopsy assessment. Children should not automatically receive adult treatment regimens; follow paediatric nephrology guidance. [1]
- After childhood IgA vasculitis, monitor urine at onset and at least monthly for 6 months or more. Confirmed nephritis needs paediatric nephrology input; consider urinalysis, eGFR and blood-pressure follow-up for at least 5 years, with individualized lifelong monitoring after treated nephritis. [1]
Limitations and use
- Regulatory approval, labelled indications and affordability of Nefecon, sparsentan and other therapies vary by country; the guideline does not establish Indian availability.
- This summary omits detailed paediatric immunosuppressive protocols, full infection screening and prophylaxis regimens, and monitoring schedules for individual medicines.
- Pregnancy medication changes require planned specialist review. Risk prediction and biopsy findings alone do not establish benefit from a particular treatment.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- IgA nephropathy and IgA vasculitis
Selected recommendation material consulted
Publication details
- Issuing organisation
- KDIGO
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.